FBIOX Overview

Inflation and Labor Market Trends: Recent data shows a decrease in inflation rates, with the year-over-year Consumer Price Index (CPI) rising 2.7% in November 2025, supporting a positive outlook for the healthcare sector, which benefits from stable demand during economic instability.

Healthcare Mutual Fund Recommendations: Three healthcare mutual funds—Fidelity Select Biotechnology Portfolio (FBIOX), Franklin Biotechnology Discovery Fund (FBDIX), and PGIM Jennison Health Sciences (PHLAX)—are recommended for long-term investment due to their strong performance, low expense ratios, and favorable Zacks Mutual Fund Rankings.

Fund Performance Details: FBIOX has 3-year and 5-year returns of 16.9% and 4.7%, respectively, while FBDIX shows 22.4% and 7.3%, and PHLAX has 14.3% and 8.9%. Each fund is managed by experienced professionals and focuses on biotechnology and health sciences.

Investment Insights: Zacks Investment Research offers insights into top-performing mutual funds and stocks, highlighting the potential for significant returns, with a particular emphasis on one stock that could outperform previous recommendations.

Investment in Healthcare Sector: The healthcare sector is considered a stable investment due to consistent demand for services and regular dividends from pharmaceutical companies. Mutual funds are recommended for investors seeking diversification and analytical insights.

Highlighted Mutual Funds: Three healthcare mutual funds are noted for their strong performance: Franklin Strategic Biotechnology Discovery Fund (FBDIX), Fidelity Select Biotechnology (FBIOX), and Fidelity Advisor Health Care Fund (FACTX), all earning a Zacks Mutual Fund Rank #1.

Performance of Funds: FBDIX has a three-year annualized return of 20.9%, FBIOX has a return of 15.1% with an expense ratio of 0.63%, and FACTX has a five-year annualized return of 5.6%, managed by Edward Yoon since 2008.

Emerging Quantum Computing Technology: Quantum computing is rapidly advancing, with major tech companies integrating it into their infrastructure. A report by Kevin Cook highlights seven stocks expected to lead in this emerging field, presenting a unique investment opportunity.

Investment in Healthcare Sector: The healthcare sector is considered a stable investment option due to consistent demand for services, with many pharmaceutical companies offering regular dividends. Mutual funds like Janus Henderson Global Life Sciences Fund, Vanguard Health Care Fund, and Fidelity Select Biotechnology fund are highlighted as strong choices for investors.

Performance of Selected Funds: Each of the mentioned mutual funds has earned a Zacks Mutual Fund Rank #1, indicating strong performance potential, with five-year annualized returns of 12.3% for JNGLX, 11.4% for VGHCX, and 9.2% for FBIOX, showcasing their financial stability and growth prospects.

Fidelity Select Biotechnology Fund Overview: Fidelity Select Biotechnology (FBIOX) is a Sector - Health mutual fund with a Zacks Mutual Fund Rank of 1 (Strong Buy), but it has shown weak performance with a 5-year annualized return of 7.03% and a negative 3-year return of -2.98%.

Cost and Volatility Analysis: FBIOX has a lower expense ratio of 0.71% compared to the category average, making it cost-effective; however, it exhibits higher volatility with a standard deviation above its peers, and a negative alpha indicating difficulty in outperforming the S&P 500 benchmark.